Take Survey
Help shape our future virtual events & community services
Take part in our survey for a chance to win a free 3-month standard gift subscription.

Profile data is unavailable for this security.

About the company

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

  • Revenue in EUR (TTM)37.55bn
  • Net income in EUR5.81bn
  • Incorporated1994
  • Employees99.41k
  • Location
    Sanofi SA54 rue la BoetiePARIS 75008FranceFRA
  • Phone+33 153774000
  • Fax+33 153774463
  • Websitehttps://www.sanofi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SAN:PAR since
Kadmon Holdings IncAnnounced08 Sep 202108 Sep 2021Announced-5.43%1.76bn
Translate Bio IncDeal completed03 Aug 202103 Aug 2021Deal completed-5.21%3.04bn
Tidal Therapeutics IncDeal completed09 Apr 202109 Apr 2021Deal completed-2.93%470.00m
Kymab Group LtdDeal completed11 Jan 202111 Jan 2021Deal completed4.37%1.45bn
Kiadis Pharma NVDeal completed02 Nov 202002 Nov 2020Deal completed6.28%254.17m
Data delayed at least 15 minutes, as of Sep 21 2021 16:38 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Eurofins Scientific SE6.39bn1.07bn23.76bn49.07k23.455.8415.593.725.314.1131.8021.320.762830.455.62123,994.5013.176.2816.358.0230.1721.2517.2710.131.2814.400.392514.7619.2022.77116.4338.2016.0236.22
Lonza Group AG3.65bn472.41m51.22bn14.41k108.717.6556.1314.026.889.5253.2597.830.2732----240,386.903.555.124.326.3541.9538.9513.0013.11--26.490.331933.197.153.4612.8321.3929.815.31
GlaxoSmithKline plc38.31bn5.11bn82.28bn94.07k16.154.5911.522.150.86960.86966.523.060.4071.674.68349,701.306.276.219.7810.3867.7568.8415.4012.690.525410.040.5415113.091.027.3523.77-7.353.330.00
Sanofi SA37.55bn5.81bn103.62bn99.41k17.731.6214.032.764.634.6329.9450.490.32921.345.36377,680.805.104.986.125.9767.6368.1315.4914.731.0628.310.255169.80-0.69621.40323.6022.79-5.281.78
Novo Nordisk A/S17.47bn5.97bn151.22bn45.97k33.1721.9922.288.6619.1319.1355.9828.850.88311.215.022,904,769.0030.1635.3057.5667.1882.9684.1034.1533.510.8012--0.173550.324.043.308.183.8728.087.29
AstraZeneca plc25.18bn3.22bn155.39bn76.10k41.059.8526.876.172.102.1016.438.740.44211.695.19284,116.805.643.888.225.4676.2380.9712.7610.191.013.460.6366141.039.161.50139.402.50-1.340.2156
Data as of Sep 21 2021. Currency figures normalised to Sanofi SA's reporting currency: Euro EUR

Institutional shareholders

16.26%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 11 Aug 202163.18m5.00%
Norges Bank Investment Managementas of 31 Dec 202028.28m2.24%
The Vanguard Group, Inc.as of 03 Sep 202127.68m2.19%
BlackRock Fund Advisorsas of 02 Sep 202119.29m1.53%
FIL Investment Advisors (UK) Ltd.as of 31 Jul 202112.17m0.96%
Lyxor International Asset Management SASas of 01 Sep 202111.72m0.93%
Amundi Asset Management SA (Investment Management)as of 14 Sep 202111.53m0.91%
BlackRock Investment Management LLCas of 16 Sep 202110.75m0.85%
BlackRock Advisors (UK) Ltd.as of 02 Sep 202110.64m0.84%
Fidelity Management & Research Co. LLCas of 31 Jul 202110.21m0.81%
More ▼
Data from 31 Dec 2020 - 15 Sep 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.